Modern aspects of the pathogenesis and treatment of psoriatic arthritis;Współczesne pogla̧dy na patogenezȩ i leczenie łuszczycy stawowej

Przeglad Dermatologiczny

Volumn 91, Issue 5, 2004, Pages 431-436

  Baran, Wojciech ^a   Nockowski, Piotr ^a   Białynicki Birula, Rafał ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Etanercept; Infliximab; Psoriatic arthritis; TNF

Indexed keywords

ETANERCEPT; INFLIXIMAB;

CLINICAL TRIAL; DATA ANALYSIS; HUMAN; IMMUNOMODULATION; MEDICAL RESEARCH; PATHOGENESIS; PSORIATIC ARTHRITIS; REVIEW;

EID: 9944253799     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Gladman D.D.: Psoriatic arthritis. Rheum Dis Clin North Am 1998, 24, 819-844.
2. Sege-Peterson K., Winchester R.: Psoriatic arthritis. [w:] Fitzpatrick's dermatology in general medicine, 5 wyd. I. Freedberg, A. Eisen, K. Wolff i inni (red.). McGraw- Hill Companies, New York, 1999, 511-533.
3. Moll J.M.H., Wright V.: Psoriatic arthritis. Semin Arthritis Rheum 1973, 3, 55-78.
4. Veale D., Rogers S., Fitzgerald O.: Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994, 33, 133-138.
5. Ross E.L., D'Cruz D., Morrow W.J.W.: Pathogenic mechanisms in psoriatic arthritis. Hosp Med 1998, 59, 534-538.
6. Fearon U., Veale J.D.: Pathogenesis of psoriatic arthritis. Clin Exp Derm 2001, 26, 333-337.
7. Eastmond C.J.: Genetics and HLA antigens: in psoriatic arthritis. Bailliere's Clin Rheumatol 1994, 8, 245-261.
8. Franks A.G. Jr.: Psoriatic arthritis and Reiter syndrome. [w:] Cutaneous manifestations of rheumatic diseases. R.D. Sontheimer, T.T. Provost (red.). Lippincott Williams & Wilkins, Philadelphia, 2003, 197-204.
9. Scarpa R., Cosentini E., Manguso F. i inni: Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". J Reumatol 2003, 30, 2638-2640.
10. Gladman D.D., Farewell V.T.: The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995, 38, 845-850.
11. Crivellato E., Zacchi T.: HLA-B39 and the axial type of psoriatic arthritis. Acta Derm Venereol (Stockh) 1987, 67, 249-250.
12. Espinoza L.R., Vasey F.B., Oh J.H. i inni: Association between HLA-BW38 and peripheral psoriatic arthritis. Arthritis Rheum 1978, 21, 72-75.
13. Christophers E., Mrowietz U.: Psoriasis. [w:] Fitzpatrick's dermatology in general medicine, 5 wyd. I. Freedberg, A. Eisen, K. Wolff i inni (red.). McGraw-Hill Companies, New York, 1999, 495-521.
14. Ritchlin C., Haas-Smith S.A., Hicks D. i inni: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25, 1544-1552.
15. Partsch G., Wagner E., Leeb B.F. i inni: T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998, 57, 691-693.
16. Partsch G., Wagner E., Leeb B.F. i inni: Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998, 25, 105-110.
17. Terajima S., Higaki M., Igarashi Y. i inni: An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis. Arch Dermatol Res 1998, 290, 146-152.
18. Bathon J.M., Martin R.W., Fleischmann R.M. i inni: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343, 1586-1593.
19. Tassiulas I., Duncan S., Centola M. i inni: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999, 60, 479-491.
20. Costello P., Bresnihan B., O'Farrelly C. i inni: Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999, 26, 1117-1124.
21. Costello P., Kane D., Curran S. i inni: Psoriatic arthritis - an enthesopathy - based disorder? Arthritis Rheum 2000, 43, 712-714.
22. Creamer D., Jagger R., Allen M. i inni: Overexpression of the angiogenic factor platelet derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997, 137, 851-855.
23. Reece R., Canete J., Parsons W. i inni: Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 1999, 42, 1481-1485.
24. Canete J.D., Pablos J.L., Sanmarti R. i inni: Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004, 50, 1636-1641.
25. Eedy D.J., Johnston C.F., Shaw C. i inni: Neuropeptides in psoriasis: an immunohistochemical and radioimmunoassay study. J Invest Dermatol 1991, 96, 434-438.
26. Veale D., Farrell M., Fitzgerald O.: Mechanisms of joint sparing in a patient with unilateral psoriatic arthritis and a long-standing hemiplegia. Br J Rheumatol 1993, 32, 413-416.
27. Punzi L., Pianon M., Bertazzolo N. i inni: Clinical, laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: a study of 25 patients. Clin Exp Rheumatol 1998, 16, 277-281.
28. Langevitz P., Baskila D., Gladman D.D.: Arthritis precipitated by physical trauma. J Rheumatol 1990, 17, 695-697.
29. Fortune D.G., Main C.J., O'Sullivan T.M. i inni: Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997, 137, 755-60.
30. Schur P.H.: Psoriatic arthritis and arthritis associated with gastrointestinal disease. [w:] Harrison's principles of internal medicine, 14 wyd. A.S. Fauci, E. Braunwald, K.J. Isselbacher i inni (red.). McGraw-Hill, New York, 1998, 1949-1951.
31. Salvarani C., Olivieri I., Cantini F. i inni: Psoriatic arthritis. Curr Opin Rheumatol 1998, 10, 299-305.
32. Seppala J., Laulainen M., Reunala T.: Comparison of etretinate (Tigason) and parenteral gold in the treatment of psoriatic arthropathy. Clin Rheumatol 1988, 7, 498-503.
33. Pitzalis C., Pipitone N.: Psoriatic arthritis. J R Soc Med 2000, 93, 412-415.
34. Baker H., Ryan T.J.: Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol 1968, 80, 771-793.
35. Braverman I.M., Cohen I., O'Keefe E.: Metabolic and ultrastructural studies in a patient with pustular psoriasis (von Zumbusch). Arch Dermatol 1972, 105, 189-196.
36. Ciompi M.L., Bazzichi L., Marotta G. i inni: Tigason (etretinate) treatment in psoriatic arthritis. Int J Tissue React 1988 10, 15-17.
37. Klinkhoff A.V., Gertner E., Chalmers A. i inni: Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989, 16, 789-791.
38. Vahlquist C., Larsson M., Ernerudh J.: Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum 1996, 39, 1519-1523.
39. Wilfert H., Honigsmann H., Steiner G.: Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol 1990, 122, 225-232.
40. Jones G., Crotty M., Brooks P.: Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000, CD000212.
41. Lebwohl M., Ali S.: Treatment of psoriasis, II: systemic therapies. J Am Acad Dermatol 2001, 45, 649-661.
42. Krueger J.G.: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46, 1-23.
43. Moreland L.W.: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med 1999, 66, 367-374.
44. Moreland L.W.: Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998, 24, 579-591.
45. Mease P.J., Goffe B.S., Metz J. i inni: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356, 385-390.
46. Mease P., Kivitz A., Burch F.: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel) results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001, 44, 90.
47. Wanke L.A., Gottlieb A.B., Mease P.J. i inni: Etanercept (ENBREL) improves health-related quality of life in patients with psoriatic arthritis [abstract]. Arthritis Rheum 2002, 46, 76.
48. Cuellar M.L., Mendez E.A., Collins R.D. i inni: Efficacy of etanercept in refractory psoriatic arthritis (PsA) [abstract]. Arthritis Rheum 2000, 43, 106.
49. Krueger G., Callis K.: Potential of Tumor Necrosis Factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol 2004, 140, 218-225.
50. Maini R.N., Breedveld F.C., Kalden J.R. i inni: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 1998, 41, 1552-1563.
51. Cauza E., Spak M., Cauza K. i inni: Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002, 22, 227-232.
52. Ogilvie A.L., Antoni C., Dechant C. i inni: Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001, 144, 587-589.
53. Salvarani C., Cantini F., Olivieri I. i inni: Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003, 49, 541-545.
54. Antoni C., Dechant C., Hanns-Martin Lorenz P.D. i inni: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002, 47, 506-512.
55. Antoni C., Kavanaugh A., Kirkham B.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract]. Prezentowane podczas: 66th Annual Scientific Meeting of the American College of Rheumatology; October 25-29.2002. New Orleans.
56. Feletar M., Brockbank J.E., Schentag C.T.: Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004, 63, 156-161.